Dianomi Therapeutics will work with Ligand on a medication delivery platform based on research from University of Wisconsin-Madison initially targeting pain disorders and osteoarthritis.

Dianomi Therapeutics, a US-based osteoarthritis treatment technology developer based on University of Wisconsin-Madison (UW-Madison) research, obtained $3m in funding on Tuesday under a partnership deal with biotech developer Ligand Pharmaceuticals.
Founded in 2017, Dianomi Therapeutics has licensed a therapeutics delivery technology called Mineral Coated Microparticle (MCM) that sustains biologics and small molecules in the body for longer to help treat pain disorders and osteoarthritis, the latter of which is often treated with surgery at present.
MCM works by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?